Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus irinotecan and temozolomide in relapsed or refractory Ewing's sarcoma (Phase 2)
2021-004734-11Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib in Ewing sarcoma of bone and Ewing sarcoma, sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started May 2022; status: active.
02
Drugs
abemaciclib
03
Conditions
Ewing sarcoma of boneEwing sarcoma
Beyond the preview
Go deeper on 2021-004734-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004734-11.